HOTAIRM1 and neoplasm: High levels of HOTAIRM1 in LC patient-derived MDSCs could inhibit the development of MDSCs and the expression of MDSC-associated suppressive molecules, via induction of homeobox A1 (HOXA1), a molecule known to delay tumor progression and enhance the anti-tumor immune response by downregulating the immunosuppressive activity of MDSCs [69].